Twist Bioscience Corporation (TWST) Q2 2021 Earnings Results

Twist Bioscience Misses on EPS, Stock Down 5.15%

Twist Bioscience's earnings report indicates ongoing challenges, particularly in achieving profitability, which contributed to a 5.15% drop in stock price. Investors may be concerned about the lack of revenue data and the absence of guidance, which adds uncertainty to the company's future performance. The management's defensive tone suggests they are aware of the hurdles ahead but remain focused on long-term growth strategies.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.78	N/A	-2.23%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed concerns about near-term performance while highlighting their commitment to future growth. They are focused on technology advancements and market positioning.

Management acknowledged challenges in achieving profitability.

They emphasized ongoing investments in technology and growth.

There was a focus on long-term strategy despite current setbacks.

Twist Bioscience Misses on EPS, Stock Down 5.15%

Key numbers

Management commentary

Twist Bioscience Corporation

More earnings this week

Twist Bioscience Misses on EPS, Stock Down 5.15%

Key numbers

Management commentary